Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Core Insights - Artelo Biosciences, Inc. is positioned to secure a development partner for ART27.13 based on positive interim results from its Phase 2 CAReS trial for cancer anorexia-cachexia syndrome (CACS) [1][4] - The interim results show significant improvements in weight, lean body mass, and activity in patients treated with ART27.13 [2] - Artelo does not foresee the need for internal funding for a Phase 3 trial, indicating a preference for a licensing transaction to maximize shareholder value [3] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer and pain [8] - ART27.13 is a novel benzimidazole derivative aimed at improving body weight, appetite, and quality of life in cancer patients, with a strong safety profile demonstrated in previous studies [5] - The company has a diversified pipeline addressing significant unmet medical needs and is also engaging in digital asset treasury strategies [8] Clinical Trial Insights - The CAReS trial is a Phase 1/2 randomized, placebo-controlled study designed to evaluate ART27.13's effectiveness in treating cancer-related anorexia and weight loss [6] - CACS affects up to 80% of advanced cancer patients and represents a market opportunity exceeding $3 billion, with no current FDA-approved treatments available [7]